Abstract
摘要
相似文献
1
[In process].[处理中]。
Med Monatsschr Pharm. 2017 Jun;40(6):271-3.
2
Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities.前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂在实际应用中的挑战与机遇
Circ Res. 2017 Aug 18;121(5):499-501. doi: 10.1161/CIRCRESAHA.117.311532.
3
JAMA PATIENT PAGE. PCSK9 Inhibitors for Treating High Cholesterol.
JAMA. 2015 Dec 1;314(21):2320. doi: 10.1001/jama.2015.13748.
4
[Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].[与低密度脂蛋白（LDL）相关的胆固醇及血管风险降低。前蛋白转化酶枯草溶菌素/kexin 9型（PCSK9）：一个新的治疗靶点]
Med Clin (Barc). 2015 Jul 20;145(2):67-9. doi: 10.1016/j.medcli.2015.04.007. Epub 2015 May 23.
5
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.基于FOURIER试验结果的PCSK9抑制剂最新成本效益分析
JAMA. 2017 Aug 22;318(8):748-750. doi: 10.1001/jama.2017.9924.
6
Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.PCSK9抑制剂治疗后的神经认知表现：证据现状
J Neurosci Res. 2018 May;96(5):762-764. doi: 10.1002/jnr.24199. Epub 2017 Nov 20.
7
Economics of lipid lowering with HMG CoA reductase inhibitors.使用HMG CoA还原酶抑制剂降低血脂的经济学分析。
Clin Cardiol. 1995 Jun;18(6):295, 363. doi: 10.1002/clc.4960180616.
8
PCSK9 inhibitors- A new age in lipid management?前蛋白转化酶枯草溶菌素9抑制剂——脂质管理的新时代？
Diab Vasc Dis Res. 2017 May;14(3):171. doi: 10.1177/1479164117708122.
9
Treatment of Hypercholesterolemia in 2015.2015年高胆固醇血症的治疗
Am J Ther. 2017 Mar/Apr;24(2):e121-e129. doi: 10.1097/MJT.0000000000000358.
10
Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.心血管预防指南建议不一致以及关于使用前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂将低密度脂蛋白胆固醇（LDL-C）水平降至零的争论。
JAMA. 2017 Aug 1;318(5):419-420. doi: 10.1001/jama.2017.6765.
Zotero 插件